← Shandong Buchang Pharmaceuticals overview

Shandong Buchang Pharmaceuticals vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shandong Buchang Pharmaceuticals Co Ltd (603858.CG)

Q3 202623 Jul – 9 Oct 2026

▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.
This is the single biggest force pushing the stock down this period.
New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.
Shows the pipeline progress that partly offsets the weak earnings.
Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.
These are the period's other concrete actions affecting the company's growth outlook.
Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.
It is a new strategic move that could support longer-term growth.

August 202623 Jul – 9 Oct 2026

▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.
This is the single biggest force pushing the stock down this period.
New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.
Shows the pipeline progress that partly offsets the weak earnings.
Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.
These are the period's other concrete actions affecting the company's growth outlook.
Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.
It is a new strategic move that could support longer-term growth.

Latest23 Jul – 9 Oct 2026

▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.
This is the single biggest force pushing the stock down this period.
New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.
Shows the pipeline progress that partly offsets the weak earnings.
Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.
These are the period's other concrete actions affecting the company's growth outlook.
Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.
It is a new strategic move that could support longer-term growth.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

August 202631 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.

Latest31 Jul – 24 Sep 2026

▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.
This is the core financial result that directly shows improved profitability and validates the growth strategy.
Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.
These regulatory milestones are new and directly add to the company's growth prospects.
Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.
This is a new major business development deal that highlights the value of its innovative pipeline.